2025 Publications

Articles
  • Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M MD, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka AP, Ferreri AJM, Merli F, Zhao WL, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens KS, Ielmini N, De Martino I, Walewski J, Trněný M, Cavalli F, Ricardi U, Johnson PWM, Davies AJ, Martelli M. Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823. Epub ahead of print. PMID: 40939190.
  • Vodicka P, Janikova A, Belada D, Hanackova V, Mocikova H, Duras J, Steinerova K, Benesova K, Konirova E, Prochazka T, Polgarova K, Masar M, Dlouha J, Blahovcova P, Trneny M. Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. Hematol Oncol. 2025 Nov;43(6):e70142. doi: 10.1002/hon.70142. PMID: 41108618; PMCID: PMC12535275.
  • Obr A, Malarikova D, Kriegova E, Urbankova H, Zemanova Z, Manakova J, Petrackova A, Vatolikova M, Berkova A, Forsterova K, Furst T, Hruskova A, Flodr P, Hanackova V, Prochazka V, Papajik T, Trneny M, Klener P. Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma. Mol Med. 2025 Sep 29;31(1):306. doi: 10.1186/s10020-025-01376-2. PMID: 41023839; PMCID: PMC12481964.
  • Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, Kopeckova K, Steinerova K, Pytlik R, Blahovcova P, Salek D, Kozak T, Bachanova V, Belada D. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. Ann Hematol. 2025 Jan;104(1):675-684. doi: 10.1007/s00277-024-06025-y. Epub 2024 Oct 1. PMID: 39352469; PMCID: PMC11868350.
  • Klanova M, Hricko S, Masar M, Vodicka P, Salek D, Kopalova N, Blahovcova P, Kuruczova D, Benesova K, Michalka J, Koren J, Klener P, Janikova A, Trneny M. Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on? Hemasphere. 2025 Sep 9;9(9):e70201. doi: 10.1002/hem3.70201. PMID: 40933274; PMCID: PMC12417966.
  • Hanáčková V, Polgárová K, Henzlová L, Zogala D, Obr A, Trněný M, Papajík T, Procházka V. Enhancing prognostic accuracy in PMBCL: semiquantitative analysis of interim PET/CT scans. Sci Rep. 2025 Oct 7;15(1):34898. doi: 10.1038/s41598-025-18649-9. PMID: 41057401; PMCID: PMC12504648.
  • Conconi A, Janikova A, Vannata B, Ramírez-Ibarguen AF, Lobetti-Bodoni C, Belada D, Pirosa MC, Mian M, Ferreri AJM, Ryan G, Pangalis G, Cabrera ME, Luminari S, Montoto S, Tsang R, Aurer I, Visco C, Casaluci GM, Prochazka V, Hricko S, Stathis A, Mazzucchelli L, Ponzoni M, Federico M, Gaidano G, Lopez-Guillermo A, Pro B, Rossi D, Cascione L, Nowakowsky G, Trneny M, Zucca E. Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2025 Jul;43(4):e70111. doi: 10.1002/hon.70111. PMID: 40544479.

2024 Publications

Articles
  • Sýkorová A, Folber F, Polgárová K, Móciková H, Ďuraš J, Steinerová K, Obr A, Heindorfer A, Ladická M, Lukáčová Ľ, Čellárová E, Plameňová I, Belada D, Janíková A, Trněný M, Jančárková T, Procházka V, Vranovský A, Králiková M, Vydra J, Smolej L, Drgoňa Ľ, Sedmina M, Čermáková E, Pytlík R. Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration. Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138. PMID: 39248284; PMCID: PMC11382134.
  • Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. PMID: 38705160.

ASH abstracts
  • Vodicka P, Benesova K, Janikova A, Belada D, Hruskova A, Mocikova H, et al. The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years. Blood. 2024;144:1697.
  • Vodicka P, Benesova K, Janikova A, Belada D, Hanackova V, Mocikova H, et al. PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial. Blood. 2024;144:1711.
  • Masar M, Vodicka P, Hricko S, Janikova A, Benesova K, Salek D, et al. Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World. Blood. 2024;144:3081.

2023 Publications

Articles
  • Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, Vockova P, Salek D, Sykorova A, Furst T, Malarikova D, Papajik T, Trneny M, Klener P. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. Ann Hematol. 2023 Jan;102(1):107-115. doi: 10.1007/s00277-022-05023-2. Epub 2022 Nov 11. PMID: 36369497; PMCID: PMC9807478.


ASH abstracts
  • Klanova M, Hricko S, Masar M, Salek D, Vodicka P, Kopalova N, et al. Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on? Blood. 2023;142:4479.
  • Vodicka P, Janikova A, Belada D, Mocikova H, Prochazka V, Duras J, Steinerova K, Campr V, Benesova K, Hricko S, Sykorova A, Blahovcova P, Jaksa R, Klanova M, Trněný M; Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?. Blood 2023; 142:4485.

2022 Publications

Articles
  • Sýkorová A, Procházka V, Móciková H, Janíková A, Pytlík R, Belada D, Benešová K, Klener P, Ďuraš J, Smolej L, Campr V, Blahovcová P, Trněný M. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index. Neoplasma. 2022 Dec;69(6):1466-1473. doi: 10.4149/neo_2022_221030N1064. PMID: 36591807.
  • Mocikova H, Pytlík R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Trneny M. Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry. Front Oncol. 2022 May 12;12:874462. doi: 10.3389/fonc.2022.874462. PMID: 35646641; PMCID: PMC9133472.
  • Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K, Kren L, Belada D, Benesova K, Dlouha J, Klener P, Procházka V, Mocikova H, Duras J, Trneny M. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). Ann Hematol. 2022 Apr;101(4):789-798. doi: 10.1007/s00277-022-04759-1. Epub 2022 Jan 21. PMID: 35061088.

ASH abstracts
  • Vodicka P, Benesova K, Janikova A, Belada D, Mocikova H, Pirnos J, et al. How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice? Blood. 2022;140:3775-6.
  • Polgarova K, Janíková A, Belada D, Prochazka V, Ďuraš J, Móciková H, et al. Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy. Blood. 2022;140:3831-2.

Publications prior to 2022

Articles
  • Procházka V, Belada D, Janíková A, Benešová K, Mociková H, Ďuraš J, Pirnos J, Kopečková K, Campr V, Fürst T, Pytlík R, Sýkorová A, Michalka J, Dlouhá J, Papajík T, Trněný M. Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. EJHaem. 2020 Jul 31;1(1):170-180. doi: 10.1002/jha2.60. PMID: 35847728; PMCID: PMC9175682.
  • Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol. 2020 Dec;191(5):e103-e106. doi: 10.1111/bjh.17063. Epub 2020 Aug 30. PMID: 32862455.
  • Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, Kriegova E, Prihodova E, Pavlistova L, Petrackova A, Zemanova Z, Trneny M, Klener P. Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers (Basel). 2020 Jul 31;12(8):2120. doi: 10.3390/cancers12082120. PMID: 32751805; PMCID: PMC7466084.
  • Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Trneny M. The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). Ann Hematol. 2020 Jul;99(7):1583-1594. doi: 10.1007/s00277-020-04099-y. Epub 2020 Jun 6. PMID: 32506244.
  • Obr A, Prochazka V, Papajik T, Klener P Jr, Janikova A, Salek D, Belada D, Pytlík R, Sykorova A, Mocikova H, Simkovic M, Campr V, Dlouha J, Furst T, Trněný M. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry†. Leuk Lymphoma. 2019 Mar;60(3):748-755. doi: 10.1080/10428194.2018.1508672. Epub 2018 Sep 6. PMID: 30188225.
  • Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13. PMID: 30474171.
  • Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019 Aug;98(8):1961-1972. doi: 10.1007/s00277-019-03694-y. Epub 2019 May 8. PMID: 31065733.
  • Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood. 2018 Nov 29;132(22):2389-2400. doi: 10.1182/blood-2018-06-855502. Epub 2018 Sep 13. PMID: 30213873.
  • Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13. PMID: 30129045.
  • Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30. PMID: 29083050.
  • Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9. PMID: 29318369.
  • Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31. PMID: 30195062.
  • Procházka V, Papajík T, Janíková A, Belada D, Kozák T, Šálek D, Sýkorová A, Móciková H, Campr V, Dlouhá J, Langová K, Fürst T, Trněný M. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. Leuk Lymphoma. 2017 Mar;58(3):601-613. doi: 10.1080/10428194.2016.1213834. Epub 2016 Sep 25. PMID: 27666539.
  • Valkova V, Jircikova J, Trnkova M, Steinerova K, Keslova P, Lanska M, Koristek Z, Raida L, Krejci M, Kruntoradova K, Dolezal T, Benesova K, Cetkovsky P, Trneny M. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. Neoplasma. 2016;63(5):743-51. doi: 10.4149/neo_2016_511. PMID: 27468878.
  • Sýkorová A, Pytlík R, Móciková H, Belada D, Benešová K, Papajík T, Janíková A, Šálek D, Procházka V, Vokurka S, Campr V, Klener P, Kubáčková K, Trněný M. Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů - doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace) [Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)]. Klin Onkol. 2016;29(4):295-302. Czech. doi: 10.14735/amko2016295. PMID: 27534788.
  • Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M; Czech Lymphoma Study Group. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leuk Lymphoma. 2016 Dec;57(12):2777-2783. doi: 10.3109/10428194.2016.1167203. Epub 2016 Apr 18. PMID: 27087066.
  • Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. Leuk Lymphoma. 2016 May;57(5):1094-103. doi: 10.3109/10428194.2015.1079313. Epub 2015 Oct 12. PMID: 26293000.
  • Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M; Czech Lymphoma Study Group. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. Leuk Lymphoma. 2015 Jan;56(1):57-64. doi: 10.3109/10428194.2014.904509. Epub 2014 Apr 29. PMID: 24628294.
  • Kalinova M, Fronkova E, Klener P, Forsterova K, Lokvenc M, Mejstrikova E, Belada D, Mocikova H, Trneny M, Kodet R, Trka J. The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma. Br J Haematol. 2015 Apr;169(1):145-8. doi: 10.1111/bjh.13182. Epub 2014 Oct 14. PMID: 25312883.
  • Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56(8):2350-6. doi: 10.3109/10428194.2014.990010. Epub 2015 Jan 21. PMID: 25426666.
  • Veselá P, Tonar Z, Šálek D, Vokurka S, Trněný M, Kodet R, Moulis M, Kašparová P, Vernerová Z, Velenská Z, Stříteský J, Michal M, Boudová L. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch. 2014 Nov;465(5):587-97. doi: 10.1007/s00428-014-1632-4. Epub 2014 Jul 22. PMID: 25048573.
  • Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, Jankovska M, Pytlik R, Belada D, Pirnos J, Moulis M, Kodet R, Michal M, Janousova E, Muzik J, Mayer J, Trněný M. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma. 2014 Apr;55(4):802-10. doi: 10.3109/10428194.2013.815349. Epub 2013 Aug 13. PMID: 23772666.
  • Procházka V, Pytlík R, Janíková A, Belada D, Sálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One. 2014 Jul 24;9(7):e102594. doi: 10.1371/journal.pone.0102594. PMID: 25058337; PMCID: PMC4109941.
  • Dědečková K, Móciková H, Belada D, Janíková A, Dolečková M, Malinová B, Feltl D, Vošmik M, Svoboda T, Marková J, Trněný M; Czech Lymphoma Study Group. Postavení radioterapie v léčbě maligních lymfomů - doporučení Kooperativní lymfomové skupiny [The role of radiotherapy in the treatment of malignant lymphomas - recommendations of the Czech Lymphoma Study Group]. Klin Onkol. 2013;26(2):99-109. Czech. doi: 10.14735/amko201399. PMID: 23718668.
  • Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920. PMID: 22873532.
  • Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. PMID: 21940214.
  • Papajik T, Myslivecek M, Skopalova M, Malan A, Buriankova E, Koza V, Hnatkova M, Trneny M, Sedova Z, Kubova Z, Koranda P, Flodr P, Jarkovsky J, Dusek L, Indrak K. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT. Neoplasma. 2011;58(4):291-7. doi: 10.4149/neo_2011_04_291. PMID: 21524147.
  • Mocikova H, Pytlik R, Markova J, Steinerova K, Kral Z, Belada D, Trnkova M, Trneny M, Koza V, Mayer J, Zak P, Kozak T. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma. 2011 Sep;52(9):1668-74. doi: 10.3109/10428194.2011.573889. Epub 2011 Jun 23. PMID: 21699377.
  • Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010 Apr 22;115(16):3215-23. doi: 10.1182/blood-2009-06-230250. Epub 2009 Dec 23. PMID: 20032498; PMCID: PMC2930903.
  • Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol. 2010 Apr;149(2):237-43. doi: 10.1111/j.1365-2141.2010.08081.x. Epub 2010 Mar 1. PMID: 20201949.
  • Valkova V, Benesova K, Vitek A, Faber E, Mayer J, Zak P, Trneny M. The results of allogeneic transplants in patients with malignant lymphoma-a retrospective analysis of data from the Czech National Registry. Neoplasma. 2009;56(1):76-83. doi: 10.4149/neo_2009_01_76. PMID: 19152250.
  • Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zapletalova J, Langova K. Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):103-7. doi: 10.5507/bp.2007.019. PMID: 17690750.
  • Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. PMID: 16648042.
  • Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, Trnený M. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial. Eur J Haematol. 2006 Dec;77(6):493-500. doi: 10.1111/j.1600-0609.2006.00741.x. Epub 2006 Oct 17. PMID: 17042769.

ASH abstracts

    • Obr A, Klener P, Janíková A, Mocikova H, Belada D, Šálek D, et al. Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group. Blood. 2021;138:4526.
    • Procházka VK, Matuštíková Š, Fürst T, Belada D, Janíková A, Benešová K, et al. Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients. Blood. 2020;136:20-1.
    • Prochazka VK, Belada D, Janikova A, Benesova K, Mocikova H, Duras J, et al. Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals. Blood. 2019;134:3983.
    • Otahal P, Janikova A, Belada D, Prochazka V, Mocikova H, Pirnos J, et al. The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). Blood. 2018;132:5413.
    • Pytlik R, Polgarova K, Trnkova M, Klener P, Blahovcova P, Vackova B, et al. Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT). Blood. 2017;130:3289.
    • Obr A, Prochazka V, Papajik T, Klener P, Janikova A, Salek D, et al. Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG). Blood. 2017;130:1498.
    • Prochazka VK, Papajik T, Janikova A, Belada D, Kozak T, Salek D, et al. Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy. Blood. 2016;128(22):1779.
    • Janikova A, Pytlik R, Klener P, Bortlicek Z, Campr V, Kopalova N, et al. Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry. Blood. 2016;128(22):3000.
    • Trneny M, Klener P, Belada D, Mocikova H, Prochazka V, Vokurka S, et al. The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI). Blood. 2014;124(21):4425.
    • Klener P, Fronkova E, Pytlik R, Kalinova M, Forsterova K, Belada D, et al. Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results. Blood. 2014;124(21):1720.
    • Prochazka V, Trneny M, Janikova A, Belada D, Kozak T, Papajik T, et al. Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database. Blood. 2013;122(21):4354.
    • Janikova A, Bortlicek Z, Campr V, Kren L, Belada D, Prochazka V, et al. Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database. Blood. 2013;122(21):4387.
    • Janikova A, Benesova K, Bortlicek Z, Campr V, Kopalova N, Belada D, et al. Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy? Blood. 2013;122(21):4388.
    • Benesova K, Trnkova M, Lanska M, Valkova V, Steinerova K, Koristek Z, et al. Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation. Blood. 2012;120(21):590.
    • Prochazka V, Trneny M, Salek D, Belada D, Kozak T, Papajik T, et al. Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project. Blood. 2010;116(21):2882.
    • Mocikova H, Pytlik R, Raida L, Zak P, Markova J, Kral Z, et al. Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic. Blood. 2009;114(22):4357.
    • Trneny M, Pytlik R, Belada D, Kubackova K, Jankovska M, Papajik T, et al. The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG. Blood. 2008;112(11):1014.
    • Trneny M, Pytlik R, Belada D, Kubackova K, Vasova I, Sykorova A, et al. Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial. Blood. 2007;110(11):21.
    • Trneny M, Belada D, Vasova I, Pytlik R, Kozak T, Sykorova A, et al. Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups. Blood. 2005;106(11):2444.
    • Pytlik R, Kubackova K, Kozak T, Belada D, Pirnos J, Jankovska M, et al. Favorable Outcome of High-Risk Mediastinal Diffuse Large B-Cell Lymphoma (DLBCL) after Dose-Intensive Chemotherapy, Rituximab and Autologous Transplant (ASCT). Blood. 2004;104(11):1322.